Table 4.

Patient outcomes: tAML/tMDS

ID no.RemissionTreatment (induction; consolidation)SurvivalCause of death
 4 Died, d 15 Standard timing 0.5 mo Progressive disease  
14 Not evaluable Standard timing; nonprotocol treatment 17 mo Graft-vs-host disease  
15 No remission Standard timing 3 mo Progressive disease  
18 Remission Standard timing; allo BMT 24 mo Progressive disease 
22 Remission Standard/intensive timing + G-CSF 11 mo Infection  
 1 No remission Intensive timing 7 mo Progressive disease  
 6 Death4-150 Intensive timing 1.3 mo Infection  
16 Died, d 3 Intensive timing 0.1 mo Progressive disease  
13 Died, d 2 Intensive timing + G-CSF < 0.1 mo Hemorrhage  
19 No remission Intensive timing 4 mo Progressive disease 
21 No remission Intensive timing 9 mo Progressive disease  
 7 No remission Intensive timing + G-CSF 6 mo Progressive disease  
20 Not evaluable Intensive timing + G-CSF 1 mo Other  
17 No remission Intensive timing + G-CSF NA Lost to follow-up  
10 Remission Intensive timing + G-CSF; chemotherapy 6 mo Infection 
 3 Remission Intensive timing; chemotherapy 17 mo Progressive disease  
 5 Remission Intensive timing; chemotherapy 30 mo Infection  
11 Remission Intensive timing + G-CSF; chemotherapy > 50 mo NA 
23 Remission Intensive timing + G-CSF; BMT4-151 > 75 mo NA  
24 Remission Intensive timing + G-CSF; chemotherapy > 58 mo NA 
 8 Remission Intensive timing; nonprotocol treatment > 92 mo NA  
12 Remission Intensive timing; allo BMT 7 mo Progressive disease 
 2 Remission Intensive timing + G-CSF; allo BMT > 74 mo NA  
 9 Remission Intensive timing + G-CSF; allo BMT > 72 mo NA 
ID no.RemissionTreatment (induction; consolidation)SurvivalCause of death
 4 Died, d 15 Standard timing 0.5 mo Progressive disease  
14 Not evaluable Standard timing; nonprotocol treatment 17 mo Graft-vs-host disease  
15 No remission Standard timing 3 mo Progressive disease  
18 Remission Standard timing; allo BMT 24 mo Progressive disease 
22 Remission Standard/intensive timing + G-CSF 11 mo Infection  
 1 No remission Intensive timing 7 mo Progressive disease  
 6 Death4-150 Intensive timing 1.3 mo Infection  
16 Died, d 3 Intensive timing 0.1 mo Progressive disease  
13 Died, d 2 Intensive timing + G-CSF < 0.1 mo Hemorrhage  
19 No remission Intensive timing 4 mo Progressive disease 
21 No remission Intensive timing 9 mo Progressive disease  
 7 No remission Intensive timing + G-CSF 6 mo Progressive disease  
20 Not evaluable Intensive timing + G-CSF 1 mo Other  
17 No remission Intensive timing + G-CSF NA Lost to follow-up  
10 Remission Intensive timing + G-CSF; chemotherapy 6 mo Infection 
 3 Remission Intensive timing; chemotherapy 17 mo Progressive disease  
 5 Remission Intensive timing; chemotherapy 30 mo Infection  
11 Remission Intensive timing + G-CSF; chemotherapy > 50 mo NA 
23 Remission Intensive timing + G-CSF; BMT4-151 > 75 mo NA  
24 Remission Intensive timing + G-CSF; chemotherapy > 58 mo NA 
 8 Remission Intensive timing; nonprotocol treatment > 92 mo NA  
12 Remission Intensive timing; allo BMT 7 mo Progressive disease 
 2 Remission Intensive timing + G-CSF; allo BMT > 74 mo NA  
 9 Remission Intensive timing + G-CSF; allo BMT > 72 mo NA 

allo BMT indicates allogeneic bone marrow transplantation; and NA, not applicable.

F4-150

The patient died prior to cycle 2 of induction.

F4-151

The patient received an autotransplantation with marrow collected at the time of his original diagnosis with Hodgkin disease.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal